Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…
Germany Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth, CEO Jörg Schüttrumpf reflects on the company’s strategic evolution, the opportunities created by its partnership with Grifols, and the role…
Europe Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As Europe rethinks the balance between affordability, resilience and innovation, Michal Nitka, SVP, Head Generics Europe & Global Head OTC at…
USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…
Taiwan Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI contrast agent for liver cancer, and MPT 1734, a nanomicelle-based therapy for prostate cancer, while outlining MegaPro’s partnership strategy, cell-tracking…
USA Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine), and with XEOMIN® (incobotulinumtoxinA) continuing to anchor its portfolio, Paolillo reflects on how Merz…
USA Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the milestone of treating 13,000 adult patients, with relapsed or refractory multiple myeloma who have received at least 1 prior line…
Europe As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over the past five years through increased investment in R&D, manufacturing, and international expansion, the company is building on the scientific…
USA Mohit Manrao, SVP and Head of US Oncology at AstraZeneca, leads the company’s effort to drive impact for cancer patients across the US. He elaborates on what it means to realise AstraZeneca’s bold ambition to eliminate cancer as a cause of death and shares how this mission goes beyond developing…
Europe The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet its ability to translate scientific excellence into timely and equitable patient access is becoming the defining challenge for the region’s…
USA Chris Posner, President of Esteve Pharmaceuticals LLC, the US affiliate of Spanish specialty player ESTEVE, speaks about the process of building its US affiliate from the ground up since joining in January. With an ambition to build a 1 billion USD global business (the US is expected to drive more…
Germany Germany’s future competitiveness begins with the policy decisions we make today Scientific breakthroughs alone are not enough to shape the future of healthcare. They must be matched by the right policy environment, sustained investment, and a shared commitment to innovation. Daniel Steiners discusses how Roche is strengthening its position across…
See our Cookie Privacy Policy Here
